Karyopharm Therapeutics Inc. buy klostergang
Summary
This prediction ended on 17.06.21 with a price of €8.53. The prediction for Karyopharm Therapeutics Inc. disappointed with a performance of -17.53%. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Karyopharm Therapeutics Inc. | -0.067% | -0.067% | -52.534% | -89.210% |
iShares Core DAX® | -2.926% | -3.811% | 9.621% | 12.399% |
iShares Nasdaq 100 | 4.462% | 7.635% | 33.690% | 60.293% |
iShares Nikkei 225® | 0.306% | -0.065% | 4.201% | 4.153% |
iShares S&P 500 | 2.488% | 4.185% | 27.301% | 50.529% |
Comments by klostergang for this prediction
In the thread Karyopharm Therapeutics Inc. diskutieren
Karyopharm with an evolving and diverse pipeline
The company’s main focuses can be broken down into 4 areas of therapy:
hematological malignancies, solid tumors, additional oncology programs,
and an “others” category. The company’s lead drug candidate is Selinexor, which is currently in 4 trials for hematological malignancies and 3 trials for solid tumors.
In April of 2017, at the American Association for Cancer Research annual meeting the company reported a 28.6% overall response rate observed in the ongoing Phase 2b SADAL study. Provided that the data is positive, the company will seek a NDA submission in 2018. Lastly, solid tumors is the third leading indication for Selinexor. In March of 2017, the company completed enrollment in the Phase 2 portion of the randomized Phase 2/3 SEAL study evaluating Selinexor versus placebo in patients with advanced liposarcoma after at least one prior therapy. The company will report the top-line data from the Phase 2 portion of this study in mid-2017.
Wall Street seems to have a positive view on KPTI’s prospects with 7 buy ratings, 0 hold ratings, and 0 sell recommendations. The consensus price target currently sits at just over $15.00 a share, which represents an upside of approximately 50%. The latest recommendation comes via Cantor Fitzgerald on May 15th, 2017. The firm reiterated their overweight rating and kept their price target at $18. Cantor stated that they think the presentation at the European Hematology Association could bring about support for KPTI’s DLBCL program. On April 7th, 2017, Jefferies reiterated a buy rating on the stock and kept their price target at $17.
Stopped prediction by klostergang for Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
30.06.17
03.12.18
03.12.18